Skip to main content
. Author manuscript; available in PMC: 2020 May 11.
Published in final edited form as: Nat Rev Clin Oncol. 2020 Feb 13;17(5):300–312. doi: 10.1038/s41571-019-0316-z

Fig. 1 |. Predictive biomarkers of response and/or survival in patients receiving immune-checkpoint inhibitors for small-cell lung cancer.

Fig. 1 |

Various tumour-based and/or blood-based assays have been evaluated for their ability to predict clinical benefit from immune-checkpoint inhibitors in patients with small-cell lung cancer. Biomarkers that are thought to continue to hold potential clinical predictive value include tumour mutational burden (TMB) and tumour-infiltrating lymphocyte RNA expression. Biomarkers that are thought to not hold predictive value based on data from larger analyses include tumour programmed cell death 1 ligand 1 (PD-L1) expression and blood-based TMB. Biomarkers that have only been evaluated in very small numbers of patients include circulating tumour cells (CTCs), combined tumour plus tumour-infiltrating immune cell PD-L1 expression, and PD-L1 expression at the tumour–stromal interface. ECM, extracellular matrix.